Gail Farfel, PhD

Gail brings more than 25 years of pharmaceutical development and regulatory rare disease experience with both large and small pharmaceutical companies. She was most recently the chief executive officer of ProMIS, a biotechnology company focused on the generation of antibody therapeutics for neurodegenerative diseases. Prior to ProMIS, Gail was the executive vice president and global chief development officer at Zogenix, Inc., where she led all product development activities to bring Fintepla (fenfluramine) to market to treat seizures in Dravet syndrome. It was through Zogenix that Gail learned the important work of the DSF, and she is proud to join the board to share her expertise to aid the advance towards better treatments and a cure for Dravet syndrome. Prior to Zogenix, Gail held executive roles at Marinus Pharmaceuticals, Novartis Corporation, and Pfizer.

Gail currently serves on the board of directors of DURECT Corporation (Nasdaq: DRRX) and AvroBio (Nasdaq: AVRO) and is a director on the Board of the American Society for Experimental Neurotherapeutics. She holds a PhD in neuropsychopharmacology from the University of Chicago, where she is a director on the Medical and Biological Sciences Alumni Board. Gail also holds a BA in biochemistry from the University of Virginia. She and her family consider New Jersey home base, though they spend time in Massachusetts, New York, California and Europe. In her free time, Gail enjoys hiking, skiing, and training her rescue dog Sadie to be a well-behaved member of the community.

Share this bio

Scroll to Top
Skip to content